Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptor-positive metastatic breast cancer – A retrospective pilot analysis and viewpoint
Introduction: Biomarkers predictive of response to mechanistic target of rapamycin (mTOR) inhibitor, everolimus, in endocrine receptor (ER)-positive metastatic breast cancer (MBC) are a work in progress. We evaluated the feasibility of directly measuring mTOR activity and phosphatase and tensin homo...
Main Authors: | Jyoti Bajpai, Anant Ramaswamy, Arun Chandrasekharan, Surya Mishra, Tanuja Shet, Sudeep Gupta, R A Badwe |
---|---|
Format: | Article |
Language: | English |
Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2017-01-01
|
Series: | South Asian Journal of Cancer |
Subjects: | |
Online Access: | http://journal.sajc.org/article.asp?issn=2278-330X;year=2017;volume=6;issue=3;spage=102;epage=105;aulast=Bajpai |
Similar Items
-
Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
by: James W. Wheless
Published: (2015-01-01) -
Derivation of Rapamycin: Adventures in Natural Product Chemistry
by: Sylvain Cottens, et al.
Published: (2019-08-01) -
Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system
by: Jing eJiang, et al.
Published: (2013-08-01) -
Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex
by: Cécile Daccord, et al.
Published: (2020-01-01) -
Clinical significance of mechanistic target of rapamycin expression in vessels that encapsulate tumor cluster‐positive hepatocellular carcinoma patients who have undergone living donor liver transplantation
by: Katsuya Toshida, et al.
Published: (2024-01-01)